Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies
Condition Advanced Cancers Estimated Enrollment: 142 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2014-0640|NCI-2015-00693 Study First Received: April 14, 2015 Last Updated: March 10, 2017 Estimated Primary Completion Date: June 2019 Primary Outcome Measures: Maximum Tolerated Dose (MTD)|Disease Control Sponsors and Collaborators: M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02419495...
Continue reading